New Risk • Jul 26
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 51% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.3x net interest cover). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.9% net profit margin). Market cap is less than US$100m (€55.1m market cap, or US$62.6m). Reported Earnings • Jul 26
Full year 2026 earnings released: EPS: kr0.42 (vs kr1.48 in FY 2025) Full year 2026 results: EPS: kr0.42 (down from kr1.48 in FY 2025). Revenue: kr432.7m (up 16% from FY 2025). Net income: kr12.5m (down 71% from FY 2025). Profit margin: 2.9% (down from 12% in FY 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Aankondiging • Jul 17
EQL Pharma AB (publ) Announces Nikunj Shah Is Not Available for Re-Election as Board Member EQL Pharma AB (publ) announced that the current board member Nikunj Shah is not available for re-election. Aankondiging • Jul 16
Eql Pharma AB Mellozzan Approval for Sale in Kazakhstan EQL Pharma's key product Mellozzan (tablets) has been approved for sale in Kazakhstan. Approval has been obtained by EQL's regional partner, Abdi Ibrahim. The approval currently covers the 3 mg strength. The Marketing Authorisation for the 5 mg strength is expected in December 2026. The launch of both strengths is expected in the fiscal year 2027/28. Mellozzan contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan is also indicated for the short-term treatment of jet lag in adults. Aankondiging • Jul 10
EQL Pharma AB (publ) to Report Q1, 2027 Results on Aug 07, 2026 EQL Pharma AB (publ) announced that they will report Q1, 2027 results on Aug 07, 2026 Aankondiging • Jun 15
EQL Pharma AB Launches Methenamine Hippurate Under Brand Name Cystohipp in Germany EQL Pharma AB's key product methenamine hippurate has now been launched in Germany by EQL Pharma AB's license partner Dr Pfleger under the EQL Pharma AB-owned brand Cystohipp. Cystohipp is the only methenamine hippurate product that is registered in Germany. German patients with recurrent urinary tract infections will now, for the first time, have access to an equivalent alternative to antibiotics-an alternative that does not increase the risk of developing antibiotic-resistant bacteria. Since 2024, methenamine hippurate is recommended by The European Association for Urology to reduce recurrent UTI episodes in woman. Cystohipp is indicated for the prophylaxis of recurrent uncomplicated urinary tract infections, which particularly affect women due to anatomical factors. As a prophylactic treatment, Cystohipp is taken twice daily as a tablet containing 1 gram of the antiseptic substance methenamine hippurate, even when the patient does not show any symptoms of an infection. The market potential is difficult to estimate as the market is being built from scratch. However, given the clear patient and societal need for alternatives to antibiotic treatment, both EQL Pharma AB and Dr Pfleger are very optimistic about very rapid growth in Germany after launch. Aankondiging • Apr 29
EQL Pharma AB (publ) Announces Departure of Chief Supply Chain Officer Magnus Erreth, Effective Mid June 2026 EQL Pharma AB (publ) announced that the current Chief Supply Chain Officer (CSCO) Magnus Erreth will leave his position. Magnus has been active in EQL Pharma since 2024 and will remain in his role until mid June 2026 and ensure a stable handover. Aankondiging • Mar 26
Eql Pharma AB Receives Marketing Authorization Approval for Mellozzan in Italy EQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco S.p.A. The launch of Mellozzan® in Italy is expected in the end of fiscal year 2026/27 or early 2027/28. Italy will be the second greenfield market for Mellozzan, after Germany, where EQL, with the help of Italfarmaco's local expertise and infrastructure, will build the brand and generate prescriptions. Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults. Aankondiging • Feb 13
EQL Pharma AB (publ), Annual General Meeting, Aug 20, 2026 EQL Pharma AB (publ), Annual General Meeting, Aug 20, 2026. Location: lund Sweden Aankondiging • Nov 16
EQL Pharma AB (publ)'s Methenamine Hippurate Gains Marketing Approval in Germany EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL owned brand Cystohipp. launch is planned for mid-2026. Cystohipp is the only methenamine hippurate product registered in Germany. German patients with recurrent urinary tract infections will now for the first time have access to an equivalent alternative to antibiotics. An alternative that does not increase the risk of developing antibiotic-resistant bacteria. Cystohipp is taken as a tablet containing 1 gram of the antiseptic substance methenamine hippurate. It is indicated as a prophylactic treatment for patients, mainly women, who suffer from recurrent urinary tract infections. As a prophylactic treatment, Cystohipp is taken twice daily by the patient even when the patient does not show any symptoms of an infection. The market potential is difficult to estimate as the market is being built from scratch. However, with such a clear patient and societal need for alternatives to antibiotic treatment, both and Dr. Pfleger are very optimistic about rapid growth in Germany after launch. Aankondiging • Nov 06
EQL Pharma AB (publ) Provides Earnings Guidance for the Full Year 2025/26 EQL Pharma AB (publ) provided earnings guidance for the full year 2025/26. For the year, Sales growth is forecast at around 30%. Sales growth for the full year 2025/26 is forecast at around 15%. Aankondiging • Oct 08
Alexander Brising to Leave EQL Pharma as Chief Commercial Officer, Effective December 2025 EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position. Alexander has been active in EQL Pharma since 2016 and will remain in his role until the end of December 2025 and ensure a stable handover. Aankondiging • Sep 24
EQL Pharma AB (publ) Provides Preliminary Financial Guidance for the Second Quarter and the Full Year 2025/26 EQL Pharma AB (publ) provided preliminary financial guidance for the second quarter and the full year 2025/26. For the second quarter, EQL Pharma announces that sales in the second quarter are expected to land just under SEK 90 million (85.2), that is a single-digit growth compared to the same quarter last year.
Full-year results for the 2025/26 financial year are expected to be closer to 15% than 30 % growth. EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made up for in the third and fourth quarters. The delivery delays have also led to postponements of launches that were supposed to take place in second quarter. These will instead take place towards the end of Third Quarter or early in fourth quarter. Profit is also affected, but not as significantly as sales. Aankondiging • Aug 22
EQL Pharma AB (publ) Elects Raymond De Vré as Board Member EQL Pharma AB (publ) at the annual general meeting held on 21 August 2025 elected Raymond De Vré as new board member for the period until the end of the next annual general meeting. Aankondiging • Aug 21
Per Ollermark Announces Not Stand for Re-Election to the Board of EQL Pharma AB (publ) The current board member Per Ollermark is not available for re-election to the board of EQL Pharma AB (publ). Aankondiging • Jul 02
Eql Pharma AB (Publ) Announces Key Product Memprex®? (Methenamine Hemurate) License Signed with Partner for Benelux EQL Pharma AB (publ) announced that its key product Memprex has now been licensed for sale in BeNeLux (Belgium, Netherlands, Luxemburg) with Goodlife Specialty BV. There is currently no product with methenamine hippurate offered in the BeNeLux. Memprex offers an alternative for treatment of recurring urinary tract infections which is both non-inferior to long-term antibiotics and which doesn't increase the risk to develop antibiotic-resistant bacteria since it is an antiseptic treatment rather than an antibiotic. For the exclusive rights to Memprex®? in BeNeLux, Goodlife will, subject to reaching agreed sales, pay a six-figure sum in EUR spread over six milestones. Aankondiging • Jun 27
EQL Pharma AB (publ) Gains Marketing Approval in France EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in France, where it is to be provided to patients by EQL's license partner Laboratoires Majorelle under the EQL owned brand Altaromin. Launch is planned for early 2026, subject to reimbursement approvals. Altaromin is the only methenamine hippurate product registered in France. French patients with recurring urinary tract infections will now for the first time have access to a non-inferior alternative to antibiotics. An alternative which doesn't increase the risk to develop antibiotic-resistant bacteria. Aankondiging • May 09
EQL Pharma AB (publ) Provides Earnings Guidance for the Period 2025/26 EQL Pharma AB (publ) provided earnings guidance for the period 2025/26. For the period, the company's Sales growth for the full year 2025/26 is forecast to be around 30%. Aankondiging • Mar 07
EQL Pharma AB (publ) Provides Earnings Guidance for the Period 2024/25 - 2028/29 EQL Pharma AB (publ) provided earnings guidance for the period 2024/25 - 2028/29. For the period, the company's target is to increase sales at an annual growth rate of 30% (CAGR), starting with the full year 2024/25 and ending the full year 2028/29. Aankondiging • Feb 05
EQL Pharma AB (publ) to Report Q4, 2025 Results on May 08, 2025 EQL Pharma AB (publ) announced that they will report Q4, 2025 results on May 08, 2025 Reported Earnings • Nov 08
Second quarter 2025 earnings released: EPS: kr0.33 (vs kr0.16 in 2Q 2024) Second quarter 2025 results: EPS: kr0.33 (up from kr0.16 in 2Q 2024). Revenue: kr85.2m (up 43% from 2Q 2024). Net income: kr9.56m (up 104% from 2Q 2024). Profit margin: 11% (up from 7.9% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Aug 19
EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board Member EQL Pharma AB (publ) announced that at the AGM held on 19 August 2024, approved the appointment of Nikunj A. Shah as New Board Member for the period until the end of the next annual general meeting. Aankondiging • Aug 13
EQL Pharma AB (publ) to Report Fiscal Year 2025 Results on May 08, 2025 EQL Pharma AB (publ) announced that they will report fiscal year 2025 results on May 08, 2025 Reported Earnings • Aug 09
First quarter 2025 earnings released First quarter 2025 results: Revenue: kr82.8m (up 47% from 1Q 2024). Net income: kr10.4m (up 53% from 1Q 2024). Profit margin: 13% (in line with 1Q 2024). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. New Risk • Aug 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (45% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change). Aankondiging • Jul 17
EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024 EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024, at 16:00 W. Europe Standard Time. Location: at the companys premises at stortorget 1, lund Sweden Aankondiging • Jul 05
EQL Pharma AB's Key Product Mellozzan[® ](melatonin) Receives Marketing Approval in Switzerland EQL Pharma AB's key product Mellozzan®? has now gained marketing approval by the Health Authorities in Switzerland, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Putter GmbH & Co. KG. Launch of Mellozzan in Switzerland is planned for the financial year 2024/25, subject to reimbursement approvals and manufacturing capabilities. In addition to Switzerland the licensee also has ongoing work for registrations and subsequent launches in Finland and the UK. In 2023, Medice launched Mellozzan®? in Denmark and Norway and this year it was launched in Germany and Austria. Mellozzan®? is the first fast-acting melatonin product registered in Switzerland. Since before, slow-acting melatonin has been available for people over 55 with sleep difficulties, but nothing for Mellozzan's normal patient group - children with ADHD and insomnia where sleep hygiene measures have not been sufficient. In addition to the countries covered by Medice, other partners for Mellozzan®? are in various stages of registration in France, Italy, the Netherlands, Turkey and Kazakhstan. Furthermore, EQL has entered into a global license agreement covering about a hundred countries with Adalvo for Mellozzan. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €5.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 14x in the Healthcare industry in Germany. Total returns to shareholders of 48% over the past three years. Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €3.61, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Healthcare industry in Germany. Total loss to shareholders of 2.4% over the past three years. Reported Earnings • May 16
Full year 2024 earnings released: EPS: kr0.78 (vs kr1.06 in FY 2023) Full year 2024 results: EPS: kr0.78 (down from kr1.06 in FY 2023). Revenue: kr264.2m (up 1.6% from FY 2023). Net income: kr22.7m (down 27% from FY 2023). Profit margin: 8.6% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Aankondiging • May 16
Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25 EQL Pharma AB (publ) provided sales guidance for the Year 2024/25. For the full year 2024/25, company project a sales growth of around 40%. Achieving this would align with company's long-term sales objectives as outlined in company's five-year financial plan. Reported Earnings • Feb 14
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr70.2m (down 12% from 3Q 2023). Net income: kr6.51m (down 46% from 3Q 2023). Profit margin: 9.3% (down from 15% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 47% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Per Svangren was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to €3.10, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 20x in the Healthcare industry in Germany. Total returns to shareholders of 25% over the past year. Reported Earnings • Nov 19
Second quarter 2024 earnings released: EPS: kr0.16 (vs kr0.26 in 2Q 2023) Second quarter 2024 results: EPS: kr0.16 (down from kr0.26 in 2Q 2023). Revenue: kr59.6m (down 19% from 2Q 2023). Net income: kr4.68m (down 37% from 2Q 2023). Profit margin: 7.9% (down from 10% in 2Q 2023). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Nov 09
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to €2.67, the stock trades at a trailing P/E ratio of 26.9x. Average trailing P/E is 21x in the Healthcare industry in Germany. Total returns to shareholders of 12% over the past year. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment deteriorates as stock falls 28% After last week's 28% share price decline to €2.53, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 20x in the Healthcare industry in Germany. Total loss to shareholders of 2.3% over the past year. New Risk • Aug 17
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 32% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risk Market cap is less than US$100m (€66.7m market cap, or US$72.5m). Reported Earnings • Jul 26
Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022) Full year 2023 results: EPS: kr1.06 (down from kr1.09 in FY 2022). Revenue: kr259.9m (down 37% from FY 2022). Net income: kr30.9m (down 2.0% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by lower expenses. Aankondiging • Jul 18
EQL Pharma AB (publ) to Report Q1, 2024 Results on Aug 16, 2023 EQL Pharma AB (publ) announced that they will report Q1, 2024 results on Aug 16, 2023 Aankondiging • Jul 07
EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023 EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023, at 16:00 Central European Standard Time. Location: Stortorget 1 Lund Sweden Agenda: To consider the adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet; the allocation of the company's result in accordance with the adopted balance sheet; to consider resolution on instruction and charter for the Nomination Committee; and to consider other matters. Reported Earnings • May 14
Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022) Full year 2023 results: EPS: kr1.06 (down from kr1.09 in FY 2022). Revenue: kr259.9m (down 37% from FY 2022). Net income: kr30.9m (down 2.0% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by lower expenses. Recent Insider Transactions • Mar 29
Founder & Chairman recently sold €1.0m worth of stock On the 24th of March, Christer Fahraeus sold around 300k shares on-market at roughly €3.34 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: kr0.26 (vs kr0.18 in 2Q 2022) Second quarter 2023 results: EPS: kr0.26 (up from kr0.18 in 2Q 2022). Revenue: kr73.3m (up 40% from 2Q 2022). Net income: kr7.46m (up 39% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022). Aankondiging • Oct 25
EQL Pharma AB (publ) Launches One-Step "Lollipop" Antigen Self-Test for Covid-19 in the Nordics - All in One - One Device, One Step EQL Pharma has started to sell the brand new Alltest Covid-19 antigen self-test of the one-step "Lollipop" model, i.e. a test that, like a lollipop, is held in the mouth for two minutes. The test reads oral saliva for Covid-19 and provides an answer within 15 minutes with 99% sensitivity. This is one of the most sensitive self-tests yet for Covid-19, even more sensitive than most of the commonly used nasal swab tests. The test's simplicity and high sensitivity make it suitable for anyone who wishes to test themselves for Covid-19 infection, especially for children and others who feel discomfort from sampling in the nasal cavity. The test is CE marked and sensitive to all known variants of the Covid-19 virus, including Omicron BA.5 which is now the most common variant in Europe. The launch of the lollipop test is seen as a generation shift in EQL Pharma self-diagnostics product line and EQL is the exclusive supplier of the Alltest device in Sweden, Denmark, Finland, Norway, Germany and Ireland. The test is available in leading pharmacies. Reported Earnings • Aug 18
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr46.1m (up 24% from 1Q 2022). Net income: kr7.39m (up 196% from 1Q 2022). Profit margin: 16% (up from 6.7% in 1Q 2022). The increase in margin was driven by higher revenue. Reported Earnings • May 15
Full year 2022 earnings released: EPS: kr1.09 (vs kr0.36 in FY 2021) Full year 2022 results: EPS: kr1.09 (up from kr0.36 in FY 2021). Revenue: kr409.8m (up 128% from FY 2021). Net income: kr31.5m (up 204% from FY 2021). Profit margin: 7.7% (up from 5.8% in FY 2021). The increase in margin was driven by higher revenue. Aankondiging • May 08
EQL Pharma Receives Approval of Glycopyrronium EQL Pharma Solution for Injection 0.2Mg/Ml from Danish Medicines Agency EQL Pharma announced that it has received the approval of Glycopyrronium EQL Pharma solution for injection 0.2mg/ml from the Danish Medicines Agency and approvals in Sweden, Norway and Finland are expected shortly. Glycopyrronium EQL Pharma contains glycopyrronium bromide and is a so-called anticholinergic which is used in hospital care, among other things, to counteract salivary secretion during operations in the mouth, throat or trachea. Glycopyrronium EQL Pharma will be EQL's third approved inpatient care product and will be sold through public tenderering in all four Nordic countries. The launch is dependent on the result of tenders for procurements but can take place at the earliest in the fourth quarter (January-March) of EQL's financial year. Aankondiging • Apr 26
EQL Pharma AB (publ) to Report Fiscal Year 2022 Results on May 13, 2022 EQL Pharma AB (publ) announced that they will report fiscal year 2022 results on May 13, 2022 Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment improved over the past week After last week's 15% share price gain to €3.20, the stock trades at a trailing P/E ratio of 52.8x. Average trailing P/E is 18x in the Healthcare industry in Germany. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €2.87, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 19x in the Healthcare industry in Germany. Reported Earnings • Feb 19
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: kr0.59 (up from kr0.07 in 3Q 2021). Revenue: kr117.6m (up 297% from 3Q 2021). Net income: kr17.2m (up kr15.0m from 3Q 2021). Profit margin: 15% (up from 7.3% in 3Q 2021). Revenue was in line with analyst estimates. Reported Earnings • Nov 12
Second quarter 2022 earnings released The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: kr52.5m (up 117% from 2Q 2021). Net income: kr5.35m (up 65% from 2Q 2021). Profit margin: 10% (down from 13% in 2Q 2021). Reported Earnings • Jul 21
Full year 2021 earnings released: EPS kr0.36 (vs kr0.09 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr179.8m (up 150% from FY 2020). Net income: kr10.4m (up 284% from FY 2020). Profit margin: 5.8% (up from 3.8% in FY 2020). 
